Delcath Systems Inc (DCTH)

[Rapture2020]

Says the guy who 8 hours ago posted the following:

“I smell a short term reversal of this pig.”

Uh huh.

What I’ve learned from this message board, if anything, is that emotion runs high. Higher than any other equity I’ve owned.

For a second I ask that look through my looking glass:

1. DCTH has an active drug portfolio.

2. DCTH has an effective drug portfolio.

3. DCTH is in receipt of an interest free loan of $10.5M; the dilution of which to secure said loan is almost paid off (at least by my numbers).

4. This loan will go directly to the completion of the trial and FDA approval.

5. The most recent 10Q has some very promising stats on the efficacy of a number of drugs within their portfolio.

6. The interim safety analysis is due within 4 weeks.

7. DCTH now has a Board Director who’s primary focus is monetizing phase 3 clinical trials post FDA approval.

8. 10Q revenue up 53%.

9. 7 employees were hired in Europe in December 2016 to help keep up with demand of DCTH’s drug portfolio.


And yet, all I read on this thread about “toxic financing”, “death spirals”, “catching a falling knife”, “pumper”,
“scam”, and of course, “bankruptcy”.

What you fail to realize is that I am divorced entirely from the past. As such, as I see DCTH as the turnaround stock of 2018. Not “a” turn around, but “the” turn around stock.

Feel free to put that in your pipe and smoke it.